Biology Reference
In-Depth Information
158. Cowan JD, Kies MS, Roth JL, Joyce RP. Nerve conduction studies
in patients treated with cis-diamminedichloroplatinum(II):
a preliminary report. Cancer Treat Rep 1980;
175. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor
prevents
experimental
cisplatin neuropathy. Ann Neurol
22.
159. Pages M, Pages AM, Bories-Azeau L. Severe sensorimotor
neuropathy after cisplatin therapy. J Neurol Neurosurg Psychiatry
1986;
64
(10-11):1119
e
80.
176. Schmidt Y, Unger JW, Bartke I, Reiter R. Effect of nerve growth
factor on peptide neurons in dorsal root ganglia after taxol or
cisplatin treatment and in diabetic (db/db) mice. Exp Neurol
1995;
1992;
31
(1):76
e
4.
160. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical
spectrum to date. Cancer Treat Rev 1985;
49
(3):333
e
23.
177. Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-
induced painful peripheral neuropathy in the rat.
132
(1):16
e
36.
161. Screnci D, McKeage MJ. Platinum neurotoxicity: clinical profiles,
experimental models and neuroprotective approaches. J Inorg
Biochem 1999;
12
(Suppl A):125
e
J Pain
41.
178. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carbo-
platin toxic effects on the peripheral nervous system of the rat.
Ann Oncol 1998;
2009;
10
(5):534
e
10.
162. Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose
carboplatin in three patients receiving multidrug chemotherapy. J
Neurol Neurosurg Psychiatry 1998;
77
(1-2):105
e
7.
179. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behav-
ioral and pharmacological description of oxaliplatin-induced
painful neuropathy in rat. Pain 2007;
9
(4):443
e
9.
163. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I
study of oxaliplatin in patients with advanced cancer. Cancer
Chemother Pharmacol 1990;
64
(5):667
e
303.
164. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxa-
liplatin-induced neurotoxicity: acute hyperexcitability and
chronic neuropathy. Muscle Nerve 2004;
25
(4):299
e
34.
180. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-
positive nociceptors to induce an oxidative stress-dependent
acute painful peripheral neuropathy. J Pain 2008;
128
(3):225
e
92.
165. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin:
a review of preclinical and clinical
29
(3):387
e
72.
181. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F,
Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated
Na(
9
(5):463
e
studies. Ann Oncol
71.
166. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced
peripheral nerve hyperexcitability. J ClinOncol 2002;
1998;
9
(10):1053
e
) channel kinetics on rat sensory neurons. Eur J Pharmacol
รพ
32.
182. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M,
Gamelin E. A possible explanation for a neurotoxic effect of the
anticancer agent oxaliplatin on neuronal voltage-gated sodium
channels. J Neurophysiol 2001;
2000;
406
(1):25
e
74.
167. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and
molecular basis of oxaliplatin neurotoxicity: current management
and development of preventive measures. Semin Oncol 2002;
20
(7):1767
e
29
(5
7.
183. Dizdaroglu M. Substrate specificities and excision kinetics of
DNA glycosylases involved in base-excision repair of oxidative
DNA damage. Mutat Res 2003;
85
(5):2293
e
33.
168. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxali-
platin-induced neurotoxicity and the development of neurop-
athy. Muscle Nerve 2005;
Suppl. 15):21
e
26.
184. Parsons JL, Dianova II . Dianov GL. APE1 is the major 3'-phos-
phoglycolate activity in human cell extracts. Nucleic Acids Res
2004;
531
(1-2):109
e
60.
169. Barajon I, Bersani M, Quartu M, et al. Neuropeptides and
morphological changes in cisplatin-induced dorsal root ganglion
neuronopathy. Exp Neurol 1996;
32
(1):51
e
104.
170. Cavaletti G, Pezzoni G, Pisano C, et al. Cisplatin-induced
peripheral neurotoxicity in rats reduces the circulating levels of
nerve growth factor. Neurosci Lett 2002;
138
(1):93
6.
185. Liu D, Croteau DL, Souza-Pinto N, et al. Evidence that OGG1
glycosylase protects neurons against oxidative DNA damage and
cell death under ischemic conditions. J Cereb Blood Flow Metab
2011;
32
(12):3531
e
e
6.
171. Verdu E, Vilches JJ, Rodriguez FJ, Ceballos D, Valero A,
Navarro X. Physiological and immunohistochemical character-
ization of cisplatin-induced neuropathy in mice. Muscle Nerve
1999;
322
(2):103
e
92.
186. Yang JL, Tadokoro T, Keijzers G, Mattson MP, Bohr VA. Neurons
efficiently repair glutamate-induced oxidative DNA damage by
a process involving CREB-mediated up-regulation of apurinic
endonuclease 1. J Biol Chem 2010;
31
(2):680
e
40.
172. Blisard KS, Rogers SL, Alexander S, Harrington DA. Neurotoxic
effects of platinum compounds in cultured dorsal root ganglion
cells. J Exp Pathol 1992;
22
(3):329
e
9.
187. Stetler RA, Gao Y, Zukin RS, et al. Apurinic/apyrimidinic
endonuclease APE1 is required for PACAP-induced neuro-
protection against global cerebral ischemia. Proc Natl Acad Sci,
USA 2010;
285
(36):28191
e
74.
173. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal
model of nociceptive peripheral neuropathy following repeated
cisplatin injections. Exp Neurol 2003;
6
(1-2):65
e
9.
188. Vasko MR, Guo C, Kelley MR. The multifunctional DNA repair/
redox enzyme Ape1/Ref-1 promotes survival of neurons after
oxidative stress. DNA Repair (Amst) 2005;
107
(7):3204
e
20.
174. De Koning P, Neijt JP, Jennekens FG, Gispen WH. Evaluation of
cis-diamminedichloroplatinum (II)
182
(1):12
e
(cisplatin) neurotoxicity in
rats. Toxicol Appl Pharmacol 1987;
89
(1):81
e
7.
4
(3):367
e
79.
